Rajfer J, Sikka S C, Rivera F, Handelsman D J
J Clin Endocrinol Metab. 1986 Nov;63(5):1193-8. doi: 10.1210/jcem-63-5-1193.
To determine the antisteroidogenic effect of ketoconazole (KTZ) in the human testis, we measured the plasma delta 5-pregnenolone, delta 5-17 alpha-hydroxypregnenolone, dehydroepiandrosterone (DHEA), progesterone, 17 alpha-hydroxyprogesterone, androstenedione (A), and testosterone (T) concentrations in three men with previously untreated metastatic prostate cancer at various time intervals for 24 h before and 48 h after the administration of 200 mg oral KTZ every 8 h. The adrenal glands of these three patients were suppressed (as measured by the plasma cortisol levels) by the administration of 1.0 mg dexamethasone daily for 7 days before and during the study. After six doses of KTZ, bilateral orchiectomy was performed, and the intratesticular concentration of the aforementioned seven steroids and the intratesticular activities of the 17 alpha-hydroxylase, 17,20-desmolase, and 17 beta-hydroxysteroid dehydrogenase enzymes in the delta 4-steroidogenic pathway were determined. These seven intratesticular steroids and three intratesticular enzyme activities were compared to those in five men with previously untreated prostate cancer who underwent orchiectomy as primary treatment for their disease. Plasma A, DHEA, and T all significantly decreased during KTZ therapy. There was no significant change in the other four steroids in the plasma. In the testis, delta 5-pregnenolone, delta 5-17 alpha-hydroxypregnenolone, and delta 4-17 alpha-hydroxyprogesterone were all significantly elevated, whereas intratesticular DHEA, A, and T were significantly decreased in the three KTZ-treated patients compared to levels in the five non-KTZ-treated patients. Measurement of the enzyme activities demonstrated a significant reduction in both 17 alpha-hydroxylase and 17,20-desmolase, but no change in 17 beta-hydroxysteroid dehydrogenase, in the KTZ-treated patients compared to the levels in the non-KTZ-treated patients. We conclude that oral KTZ decreases testicular T production by inhibiting the 17,20-desmolase and also the 17 alpha-hydroxylase steps in both the delta 4- and delta 5-T biosynthetic pathways.
为确定酮康唑(KTZ)对人睾丸的抗类固醇生成作用,我们测定了3例未经治疗的转移性前列腺癌患者在每8小时口服200 mg KTZ之前24小时及之后48小时不同时间点的血浆δ5-孕烯醇酮、δ5-17α-羟基孕烯醇酮、脱氢表雄酮(DHEA)、孕酮、17α-羟孕酮、雄烯二酮(A)和睾酮(T)浓度。在研究前及研究期间,这3例患者每日服用1.0 mg地塞米松,持续7天,其肾上腺功能受到抑制(通过血浆皮质醇水平测定)。在给予6剂KTZ后,进行双侧睾丸切除术,并测定上述7种类固醇的睾丸内浓度以及δ4-类固醇生成途径中17α-羟化酶、17,20-裂解酶和17β-羟类固醇脱氢酶的睾丸内活性。将这7种睾丸内类固醇和3种睾丸内酶活性与5例未经治疗的前列腺癌患者进行比较,这些患者接受睾丸切除术作为其疾病的主要治疗方法。在KTZ治疗期间,血浆A、DHEA和T均显著降低。血浆中其他4种类固醇无显著变化。在睾丸中,3例接受KTZ治疗的患者与5例未接受KTZ治疗的患者相比,δ5-孕烯醇酮、δ5-17α-羟基孕烯醇酮和δ4-17α-羟孕酮均显著升高,而睾丸内DHEA、A和T显著降低。酶活性测定表明,与未接受KTZ治疗的患者相比,接受KTZ治疗的患者17α-羟化酶和17,20-裂解酶均显著降低,但17β-羟类固醇脱氢酶无变化。我们得出结论,口服KTZ通过抑制δ4-和δ5-睾酮生物合成途径中的17,20-裂解酶以及17α-羟化酶步骤来降低睾丸睾酮的产生。